Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)

BACKGROUND. Angiosarcomas account for <2% of all soft tissue sarcomas. This subtype is one of the most aggressive forms of soft tissue sarcoma. The prognosis for angiosarcoma patients in the advanced phase remains poor with current cytotoxic agents (progression-free survival [PFS] time of ∼4 mont...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ray-Coquard, Isabelle, Italiano, Antoine, Bompas, Emmanuelle, Le Cesne, Axel, Robin, Yves-Marie, Chevreau, Christine, Bay, Jacques-Olivier, Bousquet, Guilhem, Piperno-Neumann, Sophie, Isambert, Nicolas, Lemaitre, Laurent, Fournier, Charles, Gauthier, Eric, Collard, Olivier, Cupissol, Didier, Clisant, Stéphanie, Blay, Jean-Yves, Penel, Nicolas
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2012
Témata:
Sarcomas
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3286175/
https://ncbi.nlm.nih.gov/pubmed/22285963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0237
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky